Does prevalence of transfusion-transmissible viral infection reflect corresponding incidence in United States blood donors?

Transfusion

Volumn 45, Issue 7, 2005, Pages 1089-1096

  Wang, Baoguang ^a   Schreiber, G B ^b   Glynn, S A ^b   Kleinman, Steven ^b   Wright, D J ^b   Murphy, E L ^b   Busch, M P ^b  

^a WESTAT   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD DONOR; DEMOGRAPHY; DISEASE MARKER; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; RISK ASSESSMENT; SAFETY; TORQUE TENO VIRUS; UNITED STATES; VIRUS INFECTION;

BLOOD BANKS; BLOOD DONORS; BLOOD TRANSFUSION; CROSS-SECTIONAL STUDIES; DELTARETROVIRUS INFECTIONS; DEMOGRAPHY; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; INCIDENCE; PREVALENCE; RISK; UNITED STATES; VIRUS DISEASES;

EID: 21644460601     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2005.00178.x     Document Type: Article

References (26)

1. Busch MP, Glynn SA, Stramer SL, et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005;45:254-64.
2. Dodd RY, Notari IVEP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002;42:975-9.
3. Busch MP. Closing the windows on viral transmission by blood transfusion. In: Stramer SL, editor. Blood safety in the new millennium. Bethesda: American Association of Blood Banks; 2001. p. 45.
4. Busch MP, Watanabe BCK, Smith JW, Hermansen SW, Thomson RA. False-negative testing errors in routine viral marker screening of blood donors. Transfusion 2000;40:585-9.
5. Glynn SA, Kleinman SH, Busch MP. International application of the incidence rate/window period model. Transfusion 2002;42:966-72.
6. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004;351:760-8.
7. Zuck TF, Thomson RA, Schreiber GB, et al. The Retrovirus Epidemiology Donor Study (REDS): rationale and methods. Transfusion 1995;35:944-51.
8. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. N Engl J Med 1996;334:1685-90.
9. Williams AE, Thomson RA, Schreiber GB, et al. Estimates of infectious disease risk factors in US blood donors. JAMA 1997;277:967-72.
10. Glynn SA, Kleinman SH, Schreiber GB, et al. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991-1996. JAMA 2000;284:229-35.
11. Wright DJ, Glynn SA, Busch M, et al. A proposed new method to estimate hepatitis B incidence rates based on HBsAg marker. Transfusion 1999;39S:106S.
12. SAS Institute Inc. SAS/STAT user's guide. Version 8. Gary (NC): The Institute; 1999.
13. van der Poel CL, Seifried E, Schaasberg WP. Paying for blood donations: still a risk? Vox Sang 2002;83:285-93.
14. Busch MP, Kleinman SH, Nemo GJ. Current and emerging infectious risks of blood transfusions. JAMA 2003;289:959-62.
15. HIV and AIDS - United States, 1981-2000 [published erratum appears in MMWR Morb Mortal Wkly Rep 2001;50:1066]. MMWR Morb Mortal Wkly Rep 2001;50:430-4.
16. Lackritz EM, Satten GA, Aberle-Grasse J, et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 1995; 333:1721-5.
17. Damesyn MA, Glynn SA, Schreiber GB, et al. Behavioral and infectious disease risks in young blood donors: implications for recruitment. Transfusion 2003;43:1596-603.
18. Anderson JE, Wilson RW, Barker P, et al. Prevalence of sexual and drug-related HIV risk behaviors in the U.S. adult population: results of the 1996 National Household Survey on drug abuse. J Acquir Immune Defic Syndr Hum Retrovirol 1999;21:148-56.
19. Sharma UK, Schreiber GB, Glynn SA, et al. Knowledge of HIV/AIDS transmission and screening in United States blood donors. Transfusion 2001;41:1341-50.
20. Glynn SA, Busch MP, Schreiber GB, et al. Effect of a national disaster on blood supply and safely: the September 11 experience. JAMA 2003;289:2246-53.
21. Stevens CE, Taylor PE, Pindyck J, et al. Epidemiology of hepatitis C virus: a preliminary study in volunteer blood donors. JAMA 1990;263:49-53.
22. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
23. Zou S, Notari EP, Stramer SL, et al. Patterns of age- and sex-specific prevalence of major blood-borne infections in United States blood donors, 1995-2002: American Red Cross blood donor study. Transfusion 2004;44:1640-7.
24. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998;47(RR-19):1-39.
25. Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000;5:578-82.
26. Murphy EL, Bryzman S, Williams AE, et al. Demographic determinants of hepatitis C virus seroprevalence among blood donors. JAMA 1996;275:995-1000.